GlassScriptPhysician profile
Stephanie Frances Lee
NPI 1659962611
$2,844.77
in general payments reported to CMS, 2019-2025
20 companies · $577 in 2025
The $577 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.53 · 2022: $859 · 2023: $751 · 2024: $622 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,949.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.06 | 2021-2025 | |
| Corium, LLC | $378.94 | 2022-2025 | Azstarys |
| Tris Pharma INC | $351.72 | 2023-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $262.29 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $235.68 | 2022-2024 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $226.65 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.84 | 2022-2024 | Caplyta |
| Lundbeck LLC | $178.15 | 2022-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $154.82 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $91.82 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $64.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $61.75 | 2024-2025 | Austedo Xr, Uzedy |
| Collegium Pharmaceutical, INC. | $43.69 | 2025 | Jornay Pm |
| Alkermes, INC. | $41.01 | 2022-2024 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $36.05 | 2022-2023 | Belsomra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $32.59 | 2022 | |
| Braeburn INC. | $18.96 | 2024 | Brixadi |
| Janssen Pharmaceuticals, INC | $17.60 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.72 | 2025 | Rejoyn |
| Biohaven Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.